Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 12, 2016, Pages 1482-1488

  Protic, Marijana ^a   Schoepfer, Alain ^b   Yawalkar, Nikhil ^c   Vavricka, Stephan ^d   Seibold, Frank ^e  

^a ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

^e University Hospital Fribourg   (Switzerland)

Author keywords

adalimumab; certolizumab pegol; Crohn s disease; inflammatory bowel disease; infliximab; Psoriasis; ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIBODY; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; STEROID; TAR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR ANTIBODY; UNCLASSIFIED DRUG; USTEKINUMAB; VITAMIN D DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PUVA; REMISSION; SKIN EXAMINATION; TREATMENT INTERRUPTION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COMPLICATION; INFLAMMATORY BOWEL DISEASES; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; SWITZERLAND; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERTOLIZUMAB PEGOL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PSORIASIS; SWITZERLAND; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84982283775     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2016.1218541     Document Type: Article

References (30)

1. J.H.Cho, S.R.Brant Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140:1704–1712.
2. M.Cargill, S.J.Schrodi, M.Chang,. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273–290.
3. A.E.Moustou, A.Matekovits, C.Dessinioti,. Cutaneous side effects of anti-tumor necrosis factor biologic therapy:a clinical review. J Am Acad Dermatol. 2009;61:486–504.
4. D.J.Najarian, A.B.Gottlieb Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805–821.
5. S.R.Vavricka, L.Brun, P.Ballabeni,. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am. J. Gastroenterol. 2011;106:110–119.
6. R.Denadai, F.V.Teixeira, F.Steinwurz,. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease:a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517–524.
7. M.Iborra, B.Beltrán, G.Bastida,. Infliximab and adalimumab-induced psoriasis in Crohn's disease:a paradoxical side effect. J Crohns Colitis. 2011;5:157–161.
8. C.Tillack, L.M.Ehmann, M.Friedrich,. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–577.
9. G.Fiorino, M.Allez, A.Malesci,. Review article:anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921–927.
10. A.K.Palucka, J.P.Blanck, L.Bennett,. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102:3372–3377.
11. O.H.Nielsen, J.T.Bjerrum, J.B.Seidelin,. Biological treatment of Crohn's disease. Dig Dis. 2012;30:121–133.
12. J.F.Brandse, L.M.Vos, J.Jansen,. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohns Colitis. 2015;9:973–981.
13. C.Coutzac, J.Chapuis, F.Poullenot,. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease:a case-control study. J Crohns Colitis. 2015;9:982–987.
14. A.Afzali, C.L.Wheat, J.K.Hu,. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease:a single academic center case series. J Crohns Colitis. 2014;8:480–488.
15. A.Robinson, M.Kardos, A.B.Kimball Physician global assessment (PGA) and psoriasis area and severity index (PASI):why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–375.
16. J.Satsangi, M.S.Silverberg, S.Vermeire,. The Montreal classification of inflammatory bowel disease:controversies, consensus, and implications. Gut. 2006;55:749–753.
17. V.Pittet, P.Juillerat, C.Mottet,. Cohort profile:the Swiss inflammatory bowel disease cohort study (SIBDCS). Int J Epidemiol. 2009;38:922–931.
18. C.Steenholdt, K.Bendtzen, J.Brynskov,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011;46:310–318.
19. R.P.Nair, K.C.Duffin, C.Helms,. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41:199–204.
20. V.M.Yates, G.Watkinson, A.Kelman Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol. 1982;106:323–330.
21. A.N.Collamer, K.T.Guerrero, Henning,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy:a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001.
22. J.M.Ko, A.B.Gottlieb, J.F.Kerbleski Induction and exacerbation of psoriasis with TNF-blockade therapy:a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100–108.
23. M.J.Harrison, W.G.Dixon, K.D.Watson,. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy:results from the British society for rheumatology biologics register. Ann Rheum Dis. 2009;68:209–215.
24. J.F.Rahier, S.Buche, L.Peyrin-Biroulet,. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048–1055.
25. J.Torres, S.Buche, E.Delaporte,. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2013;19:1086–1098.
26. I.Guerra, A.Algaba, J.L.Pérez-Calle,. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease:a report of 21 cases. J Crohns Colitis. 2012;6:518–523.
27. I.Cleynen, W.Van Moerkercke, M.Juergens,. Anti TNF induced cutaneous lesions in IBD patients:characterization and search for predisposing factors. Gut. 2010;59:A1.
28. G.Michaelsson, U.Kajermo, A.Michaëlsson,. Infliximab can precipitate as well as worsen palmoplantar pustulosis:possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol. 2005;153:1243–1244.
29. G.Cullen, D.Kroshinsky, A.S.Cheifetz,. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease:a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318–1327.
30. K.S.Nanda, A.S.Cheifetz, A.C.Moss Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD):a meta-analysis. Am J Gastroenterol. 2013;108:40–47.